Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreatic Neoplasms | 43 | 2023 | 5444 | 1.800 |
Why?
|
Carcinoma, Pancreatic Ductal | 19 | 2023 | 1758 | 1.510 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 63 | 2025 | 11868 | 1.330 |
Why?
|
Stomach Neoplasms | 16 | 2023 | 1471 | 1.290 |
Why?
|
Antineoplastic Agents | 40 | 2020 | 13648 | 1.270 |
Why?
|
Deoxycytidine | 23 | 2020 | 889 | 1.270 |
Why?
|
Adenocarcinoma | 37 | 2023 | 6364 | 1.270 |
Why?
|
Liver Neoplasms | 27 | 2023 | 4353 | 1.240 |
Why?
|
Fluorouracil | 43 | 2023 | 1648 | 1.220 |
Why?
|
Proto-Oncogene Proteins c-met | 13 | 2020 | 561 | 1.170 |
Why?
|
Carcinoma, Hepatocellular | 17 | 2023 | 2329 | 1.130 |
Why?
|
Colorectal Neoplasms | 27 | 2023 | 6942 | 0.980 |
Why?
|
Neoadjuvant Therapy | 29 | 2023 | 2895 | 0.970 |
Why?
|
Esophageal Neoplasms | 12 | 2021 | 1661 | 0.920 |
Why?
|
Rectal Neoplasms | 17 | 2021 | 1182 | 0.910 |
Why?
|
Neuroendocrine Tumors | 11 | 2025 | 654 | 0.880 |
Why?
|
Camptothecin | 14 | 2017 | 600 | 0.870 |
Why?
|
Protein-Tyrosine Kinases | 11 | 2023 | 2423 | 0.840 |
Why?
|
Gastrointestinal Neoplasms | 9 | 2024 | 961 | 0.800 |
Why?
|
Leucovorin | 21 | 2023 | 641 | 0.770 |
Why?
|
Pyridines | 15 | 2016 | 2888 | 0.760 |
Why?
|
Protein Kinase Inhibitors | 20 | 2024 | 5696 | 0.710 |
Why?
|
Proto-Oncogene Proteins | 10 | 2023 | 4520 | 0.660 |
Why?
|
Anus Neoplasms | 5 | 2024 | 336 | 0.650 |
Why?
|
Benzenesulfonates | 3 | 2009 | 170 | 0.590 |
Why?
|
Bile Duct Neoplasms | 6 | 2024 | 626 | 0.570 |
Why?
|
Neoplasms | 27 | 2024 | 22340 | 0.560 |
Why?
|
Cholangiocarcinoma | 6 | 2024 | 578 | 0.550 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2020 | 422 | 0.550 |
Why?
|
Pyrazoles | 12 | 2016 | 2033 | 0.540 |
Why?
|
Maximum Tolerated Dose | 17 | 2024 | 898 | 0.540 |
Why?
|
Triazoles | 2 | 2020 | 897 | 0.530 |
Why?
|
Drug Resistance, Neoplasm | 15 | 2020 | 5337 | 0.460 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 8 | 2024 | 1761 | 0.440 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 11 | 2020 | 5389 | 0.440 |
Why?
|
Lung Neoplasms | 18 | 2021 | 13451 | 0.430 |
Why?
|
Antimetabolites, Antineoplastic | 10 | 2014 | 647 | 0.430 |
Why?
|
Tryptamines | 1 | 2014 | 94 | 0.430 |
Why?
|
Levonorgestrel | 1 | 2014 | 76 | 0.430 |
Why?
|
Ethinyl Estradiol | 1 | 2014 | 111 | 0.430 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2018 | 451 | 0.420 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2014 | 116 | 0.420 |
Why?
|
Serotonin Receptor Agonists | 1 | 2014 | 151 | 0.420 |
Why?
|
Clinical Trials, Phase I as Topic | 5 | 2014 | 330 | 0.410 |
Why?
|
Gene Amplification | 6 | 2020 | 1091 | 0.390 |
Why?
|
Organoplatinum Compounds | 10 | 2019 | 404 | 0.390 |
Why?
|
Middle Aged | 133 | 2025 | 223009 | 0.390 |
Why?
|
Carbazoles | 1 | 2014 | 229 | 0.390 |
Why?
|
Aged | 118 | 2025 | 171117 | 0.370 |
Why?
|
Paclitaxel | 4 | 2016 | 1728 | 0.370 |
Why?
|
Antibodies, Monoclonal | 17 | 2017 | 9249 | 0.350 |
Why?
|
Receptor Protein-Tyrosine Kinases | 9 | 2021 | 1624 | 0.340 |
Why?
|
Cytidine Deaminase | 1 | 2012 | 250 | 0.340 |
Why?
|
Lymphopenia | 2 | 2024 | 297 | 0.340 |
Why?
|
Humans | 202 | 2025 | 765968 | 0.340 |
Why?
|
Female | 144 | 2025 | 396112 | 0.330 |
Why?
|
Esophagogastric Junction | 4 | 2020 | 351 | 0.330 |
Why?
|
Aged, 80 and over | 60 | 2025 | 59489 | 0.330 |
Why?
|
Male | 140 | 2025 | 363698 | 0.330 |
Why?
|
Neoplasm Recurrence, Local | 14 | 2021 | 9373 | 0.320 |
Why?
|
Albumins | 1 | 2012 | 577 | 0.320 |
Why?
|
Treatment Outcome | 59 | 2024 | 65188 | 0.310 |
Why?
|
ras Proteins | 4 | 2014 | 1053 | 0.310 |
Why?
|
Microsatellite Instability | 4 | 2019 | 728 | 0.310 |
Why?
|
raf Kinases | 2 | 2007 | 116 | 0.310 |
Why?
|
Combined Modality Therapy | 18 | 2022 | 8529 | 0.300 |
Why?
|
Pancreatectomy | 6 | 2023 | 820 | 0.300 |
Why?
|
Antineoplastic Agents, Phytogenic | 4 | 2006 | 616 | 0.290 |
Why?
|
Enzyme Inhibitors | 4 | 2006 | 3715 | 0.290 |
Why?
|
Intraoperative Care | 4 | 2019 | 760 | 0.290 |
Why?
|
Angiogenesis Inhibitors | 9 | 2017 | 2056 | 0.290 |
Why?
|
Adult | 104 | 2025 | 223044 | 0.290 |
Why?
|
Retrospective Studies | 51 | 2024 | 81514 | 0.280 |
Why?
|
Survival Rate | 24 | 2024 | 12795 | 0.280 |
Why?
|
Positron-Emission Tomography | 10 | 2022 | 6547 | 0.270 |
Why?
|
Mutation | 22 | 2024 | 30198 | 0.270 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 3 | 2018 | 548 | 0.260 |
Why?
|
Peritoneal Neoplasms | 2 | 2023 | 703 | 0.260 |
Why?
|
Liver Cirrhosis | 2 | 2023 | 1959 | 0.250 |
Why?
|
Prognosis | 26 | 2024 | 29922 | 0.240 |
Why?
|
Exons | 4 | 2020 | 2391 | 0.230 |
Why?
|
Vascular Endothelial Growth Factor A | 10 | 2022 | 3513 | 0.230 |
Why?
|
Pyrimidinones | 2 | 2024 | 384 | 0.230 |
Why?
|
Dose-Response Relationship, Drug | 11 | 2019 | 10729 | 0.230 |
Why?
|
Gastrectomy | 3 | 2020 | 694 | 0.230 |
Why?
|
Biliary Tract Neoplasms | 2 | 2020 | 186 | 0.220 |
Why?
|
Purine Nucleosides | 1 | 2003 | 30 | 0.220 |
Why?
|
Alkyl and Aryl Transferases | 1 | 2004 | 89 | 0.220 |
Why?
|
Disease-Free Survival | 17 | 2020 | 6832 | 0.210 |
Why?
|
Gene Rearrangement | 4 | 2014 | 1144 | 0.210 |
Why?
|
Isocitrate Dehydrogenase | 3 | 2015 | 954 | 0.210 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 2 | 2010 | 660 | 0.210 |
Why?
|
Neoplasm Staging | 17 | 2021 | 11206 | 0.200 |
Why?
|
bcl-X Protein | 1 | 2024 | 414 | 0.200 |
Why?
|
Portal Vein | 2 | 2023 | 435 | 0.200 |
Why?
|
Taxoids | 2 | 2004 | 665 | 0.190 |
Why?
|
Drug Administration Schedule | 12 | 2014 | 4850 | 0.190 |
Why?
|
Coronary Vasospasm | 1 | 2022 | 81 | 0.190 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2022 | 222 | 0.190 |
Why?
|
Pyridones | 2 | 2024 | 816 | 0.190 |
Why?
|
Losartan | 2 | 2023 | 263 | 0.190 |
Why?
|
Imidazoles | 2 | 2005 | 1162 | 0.190 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2024 | 4044 | 0.190 |
Why?
|
Benzodiazepines | 2 | 2005 | 1136 | 0.190 |
Why?
|
Survival Analysis | 20 | 2021 | 10070 | 0.180 |
Why?
|
Appendiceal Neoplasms | 1 | 2023 | 155 | 0.180 |
Why?
|
Migraine Disorders | 1 | 2014 | 1732 | 0.180 |
Why?
|
Liver Neoplasms, Experimental | 1 | 2021 | 190 | 0.180 |
Why?
|
Kaplan-Meier Estimate | 11 | 2020 | 6499 | 0.180 |
Why?
|
Pancreaticoduodenectomy | 3 | 2019 | 512 | 0.170 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2021 | 95 | 0.170 |
Why?
|
Proto-Oncogene Proteins B-raf | 6 | 2023 | 2054 | 0.170 |
Why?
|
Administration, Oral | 11 | 2014 | 4015 | 0.170 |
Why?
|
Antigens, Ly | 2 | 2017 | 296 | 0.160 |
Why?
|
Follow-Up Studies | 16 | 2024 | 39193 | 0.160 |
Why?
|
Receptors, CXCR4 | 2 | 2017 | 728 | 0.160 |
Why?
|
Radiodermatitis | 1 | 2019 | 58 | 0.160 |
Why?
|
Dacarbazine | 3 | 2012 | 552 | 0.160 |
Why?
|
Aniline Compounds | 1 | 2024 | 1075 | 0.150 |
Why?
|
Feasibility Studies | 4 | 2023 | 5302 | 0.150 |
Why?
|
Quinazolines | 8 | 2007 | 1364 | 0.150 |
Why?
|
DNA, Neoplasm | 2 | 2023 | 1742 | 0.150 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 120 | 0.150 |
Why?
|
Receptors, Growth Factor | 4 | 2011 | 324 | 0.150 |
Why?
|
Radiotherapy Dosage | 9 | 2019 | 2865 | 0.150 |
Why?
|
Indoles | 3 | 2011 | 1839 | 0.150 |
Why?
|
Chemotherapy, Adjuvant | 8 | 2021 | 3537 | 0.150 |
Why?
|
Monocytes | 2 | 2017 | 2595 | 0.150 |
Why?
|
In Situ Hybridization, Fluorescence | 7 | 2021 | 2505 | 0.140 |
Why?
|
Neoplasm, Residual | 2 | 2021 | 1009 | 0.140 |
Why?
|
Radiotherapy | 3 | 2021 | 1494 | 0.140 |
Why?
|
Angiotensins | 1 | 2017 | 139 | 0.130 |
Why?
|
Liver Failure | 1 | 2019 | 252 | 0.130 |
Why?
|
Niacinamide | 3 | 2009 | 419 | 0.130 |
Why?
|
Tissue Distribution | 2 | 2019 | 2266 | 0.130 |
Why?
|
Colonic Neoplasms | 3 | 2018 | 2531 | 0.130 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2011 | 752 | 0.130 |
Why?
|
Salvage Therapy | 4 | 2014 | 1272 | 0.130 |
Why?
|
Neoplasm Metastasis | 12 | 2020 | 4893 | 0.130 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 258 | 0.130 |
Why?
|
Placenta Diseases | 1 | 2018 | 199 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2024 | 981 | 0.130 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2018 | 170 | 0.130 |
Why?
|
Magnetic Resonance Imaging | 9 | 2022 | 36532 | 0.130 |
Why?
|
Genetic Heterogeneity | 2 | 2019 | 735 | 0.130 |
Why?
|
Laparotomy | 1 | 2018 | 460 | 0.130 |
Why?
|
Pyrazines | 3 | 2013 | 1204 | 0.130 |
Why?
|
Dyspnea | 1 | 2023 | 1352 | 0.120 |
Why?
|
Phenylurea Compounds | 3 | 2009 | 536 | 0.120 |
Why?
|
Cyclopentanes | 1 | 2015 | 86 | 0.120 |
Why?
|
Carcinoid Tumor | 3 | 2009 | 225 | 0.120 |
Why?
|
Photons | 1 | 2019 | 572 | 0.120 |
Why?
|
Farnesyltranstransferase | 2 | 2005 | 70 | 0.120 |
Why?
|
Bone Marrow Diseases | 1 | 2017 | 234 | 0.120 |
Why?
|
Chemokine CXCL12 | 3 | 2017 | 455 | 0.120 |
Why?
|
Infusions, Intravenous | 8 | 2013 | 2229 | 0.120 |
Why?
|
Fluorodeoxyglucose F18 | 4 | 2022 | 2024 | 0.120 |
Why?
|
Immunotherapy | 3 | 2021 | 4752 | 0.110 |
Why?
|
Molecular Targeted Therapy | 4 | 2021 | 2822 | 0.110 |
Why?
|
Sulfonamides | 1 | 2024 | 1984 | 0.110 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2021 | 1608 | 0.110 |
Why?
|
Receptors, Chemokine | 1 | 2017 | 651 | 0.110 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2018 | 784 | 0.110 |
Why?
|
Bile Ducts, Intrahepatic | 2 | 2014 | 307 | 0.110 |
Why?
|
Spermine | 1 | 2013 | 70 | 0.110 |
Why?
|
Disease Progression | 12 | 2022 | 13632 | 0.110 |
Why?
|
Pyrroles | 2 | 2010 | 1119 | 0.110 |
Why?
|
Tumor Microenvironment | 3 | 2023 | 3946 | 0.110 |
Why?
|
Area Under Curve | 4 | 2005 | 1638 | 0.110 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2015 | 248 | 0.100 |
Why?
|
Sirolimus | 2 | 2011 | 1545 | 0.100 |
Why?
|
Anal Canal | 3 | 2020 | 376 | 0.100 |
Why?
|
Blood Vessels | 1 | 2018 | 1113 | 0.100 |
Why?
|
Biostatistics | 1 | 2014 | 162 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2020 | 3655 | 0.100 |
Why?
|
Quinolines | 1 | 2018 | 769 | 0.100 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 169 | 0.100 |
Why?
|
Glutarates | 1 | 2014 | 243 | 0.100 |
Why?
|
Menstruation | 1 | 2014 | 309 | 0.100 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 2 | 2018 | 561 | 0.100 |
Why?
|
Esophagectomy | 1 | 2016 | 477 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 2024 | 1640 | 0.100 |
Why?
|
Psychodidae | 1 | 2011 | 27 | 0.100 |
Why?
|
Insect Control | 1 | 2011 | 28 | 0.100 |
Why?
|
Neutropenia | 1 | 2017 | 893 | 0.090 |
Why?
|
Radiotherapy, Adjuvant | 5 | 2015 | 1776 | 0.090 |
Why?
|
Venous Thrombosis | 1 | 2021 | 1327 | 0.090 |
Why?
|
beta Karyopherins | 1 | 2011 | 46 | 0.090 |
Why?
|
Ovarian Neoplasms | 2 | 2006 | 4900 | 0.090 |
Why?
|
Cancer Care Facilities | 1 | 2014 | 426 | 0.090 |
Why?
|
Cecal Neoplasms | 1 | 2011 | 27 | 0.090 |
Why?
|
Sample Size | 1 | 2014 | 845 | 0.090 |
Why?
|
Insect Vectors | 1 | 2011 | 136 | 0.090 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1490 | 0.090 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2015 | 618 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 8 | 2021 | 20659 | 0.090 |
Why?
|
Menstrual Cycle | 1 | 2014 | 540 | 0.090 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2010 | 69 | 0.080 |
Why?
|
Patient Discharge | 1 | 2023 | 3461 | 0.080 |
Why?
|
Chemokine CXCL6 | 1 | 2009 | 14 | 0.080 |
Why?
|
Gallbladder Neoplasms | 1 | 2011 | 189 | 0.080 |
Why?
|
Granuloma, Plasma Cell | 1 | 2010 | 80 | 0.080 |
Why?
|
Insecticides | 1 | 2011 | 203 | 0.080 |
Why?
|
Radiation Injuries | 1 | 2017 | 1181 | 0.080 |
Why?
|
Thrombosis | 1 | 2023 | 2949 | 0.080 |
Why?
|
Neuropilin-1 | 1 | 2009 | 90 | 0.080 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 1643 | 0.080 |
Why?
|
DNA Damage | 1 | 2019 | 2457 | 0.080 |
Why?
|
Prospective Studies | 12 | 2024 | 54802 | 0.080 |
Why?
|
Abdominal Neoplasms | 1 | 2010 | 284 | 0.080 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 2009 | 82 | 0.080 |
Why?
|
Guanine | 1 | 2010 | 282 | 0.080 |
Why?
|
Glutamates | 1 | 2010 | 384 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2019 | 8611 | 0.080 |
Why?
|
CA-19-9 Antigen | 2 | 2022 | 109 | 0.080 |
Why?
|
Cohort Studies | 7 | 2023 | 41649 | 0.080 |
Why?
|
Carcinoembryonic Antigen | 2 | 2023 | 337 | 0.080 |
Why?
|
Vinblastine | 2 | 2006 | 483 | 0.070 |
Why?
|
Radiosurgery | 1 | 2017 | 1328 | 0.070 |
Why?
|
Neutrophils | 2 | 2017 | 3776 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2593 | 0.070 |
Why?
|
Point Mutation | 1 | 2013 | 1590 | 0.070 |
Why?
|
Tubulin | 1 | 2011 | 692 | 0.070 |
Why?
|
Cell Line, Tumor | 6 | 2021 | 17075 | 0.070 |
Why?
|
Neovascularization, Pathologic | 3 | 2009 | 2631 | 0.070 |
Why?
|
Mitomycin | 2 | 2019 | 261 | 0.070 |
Why?
|
Rectum | 2 | 2019 | 896 | 0.070 |
Why?
|
Melanoma | 2 | 2023 | 5719 | 0.070 |
Why?
|
Standard of Care | 2 | 2022 | 567 | 0.070 |
Why?
|
DNA Mismatch Repair | 2 | 2021 | 433 | 0.070 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2011 | 341 | 0.070 |
Why?
|
Vascular Endothelial Growth Factors | 2 | 2006 | 754 | 0.070 |
Why?
|
Drug Delivery Systems | 2 | 2016 | 2207 | 0.070 |
Why?
|
Oxonic Acid | 1 | 2006 | 31 | 0.070 |
Why?
|
Tegafur | 1 | 2006 | 39 | 0.070 |
Why?
|
GTP Phosphohydrolases | 2 | 2024 | 523 | 0.070 |
Why?
|
Radiopharmaceuticals | 2 | 2022 | 2699 | 0.070 |
Why?
|
DNA Mutational Analysis | 3 | 2010 | 4108 | 0.060 |
Why?
|
Digestive System Neoplasms | 1 | 2006 | 82 | 0.060 |
Why?
|
Survivors | 2 | 2009 | 2372 | 0.060 |
Why?
|
Cisplatin | 3 | 2006 | 1658 | 0.060 |
Why?
|
Boronic Acids | 2 | 2006 | 916 | 0.060 |
Why?
|
Anticoagulants | 1 | 2021 | 4862 | 0.060 |
Why?
|
Postoperative Complications | 2 | 2020 | 15747 | 0.060 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2006 | 70 | 0.060 |
Why?
|
Radiotherapy, Conformal | 2 | 2011 | 533 | 0.060 |
Why?
|
Biopsy | 4 | 2018 | 6763 | 0.060 |
Why?
|
Haemophilus Vaccines | 1 | 2005 | 70 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2022 | 2942 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2011 | 2056 | 0.060 |
Why?
|
Tumor Burden | 3 | 2017 | 1885 | 0.060 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2021 | 720 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5891 | 0.060 |
Why?
|
Time Factors | 9 | 2018 | 40065 | 0.060 |
Why?
|
Quality of Life | 2 | 2023 | 13462 | 0.060 |
Why?
|
Tetanus Toxoid | 1 | 2005 | 188 | 0.060 |
Why?
|
Epidermal Growth Factor | 1 | 2007 | 698 | 0.060 |
Why?
|
Data Interpretation, Statistical | 1 | 2014 | 2686 | 0.060 |
Why?
|
Brain Neoplasms | 2 | 2018 | 9071 | 0.060 |
Why?
|
Dihydrouracil Dehydrogenase (NADP) | 1 | 2004 | 17 | 0.060 |
Why?
|
Thymidylate Synthase | 1 | 2004 | 73 | 0.060 |
Why?
|
Double-Blind Method | 2 | 2019 | 12437 | 0.060 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2004 | 105 | 0.050 |
Why?
|
Gastrointestinal Diseases | 2 | 2010 | 1203 | 0.050 |
Why?
|
Pheochromocytoma | 1 | 2006 | 323 | 0.050 |
Why?
|
Animals | 12 | 2022 | 168764 | 0.050 |
Why?
|
Pyrimidines | 1 | 2015 | 3047 | 0.050 |
Why?
|
Hypertension | 2 | 2022 | 8626 | 0.050 |
Why?
|
Mesenteric Veins | 1 | 2023 | 86 | 0.050 |
Why?
|
Staurosporine | 1 | 2004 | 240 | 0.050 |
Why?
|
Somatostatin | 1 | 2025 | 459 | 0.050 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2004 | 132 | 0.050 |
Why?
|
Ischemic Preconditioning | 1 | 2003 | 89 | 0.050 |
Why?
|
CpG Islands | 1 | 2007 | 1207 | 0.050 |
Why?
|
Treatment Failure | 3 | 2017 | 2652 | 0.050 |
Why?
|
Models, Chemical | 1 | 2004 | 608 | 0.050 |
Why?
|
Gene Expression Profiling | 2 | 2015 | 9525 | 0.050 |
Why?
|
Protein Kinases | 1 | 2008 | 1611 | 0.050 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2006 | 488 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2006 | 878 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2022 | 161 | 0.050 |
Why?
|
Pneumococcal Vaccines | 1 | 2005 | 414 | 0.050 |
Why?
|
Mice, Inbred C57BL | 5 | 2021 | 22332 | 0.050 |
Why?
|
Patient Participation | 1 | 2010 | 1455 | 0.040 |
Why?
|
Lamivudine | 1 | 2022 | 368 | 0.040 |
Why?
|
Nitrates | 1 | 2022 | 260 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2006 | 1333 | 0.040 |
Why?
|
Proportional Hazards Models | 4 | 2019 | 12509 | 0.040 |
Why?
|
Fatal Outcome | 2 | 2018 | 1831 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10261 | 0.040 |
Why?
|
Young Adult | 7 | 2020 | 59889 | 0.040 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2006 | 730 | 0.040 |
Why?
|
Genes, MHC Class I | 1 | 2021 | 236 | 0.040 |
Why?
|
Liver | 2 | 2018 | 7562 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2021 | 239 | 0.040 |
Why?
|
Nitric Oxide Synthase | 1 | 2003 | 911 | 0.040 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 634 | 0.040 |
Why?
|
Massachusetts | 4 | 2020 | 8875 | 0.040 |
Why?
|
Endosonography | 1 | 2003 | 626 | 0.040 |
Why?
|
Infarction, Middle Cerebral Artery | 1 | 2003 | 485 | 0.040 |
Why?
|
Age Factors | 4 | 2023 | 18380 | 0.040 |
Why?
|
Lymph Node Excision | 2 | 2016 | 1259 | 0.040 |
Why?
|
Preoperative Period | 1 | 2022 | 566 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 784 | 0.040 |
Why?
|
Blood Loss, Surgical | 1 | 2023 | 629 | 0.040 |
Why?
|
DNA | 2 | 2024 | 7202 | 0.040 |
Why?
|
Genotype | 5 | 2017 | 13024 | 0.040 |
Why?
|
Severity of Illness Index | 2 | 2014 | 15880 | 0.040 |
Why?
|
Radiography | 4 | 2012 | 6919 | 0.040 |
Why?
|
Killer Cells, Natural | 2 | 2018 | 2210 | 0.040 |
Why?
|
Colostomy | 1 | 2019 | 107 | 0.040 |
Why?
|
Calcium Channel Blockers | 1 | 2022 | 686 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2018 | 3608 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 714 | 0.040 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 50 | 0.040 |
Why?
|
Drug Design | 1 | 2003 | 1042 | 0.040 |
Why?
|
Vascular Patency | 1 | 2021 | 912 | 0.040 |
Why?
|
Mice, Inbred BALB C | 2 | 2017 | 6220 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2013 | 3181 | 0.040 |
Why?
|
Pyrrolidinones | 1 | 2018 | 116 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 862 | 0.040 |
Why?
|
Mice | 7 | 2021 | 81819 | 0.040 |
Why?
|
Chemokine CX3CL1 | 1 | 2017 | 60 | 0.030 |
Why?
|
Lymphatic Metastasis | 2 | 2019 | 2887 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2018 | 315 | 0.030 |
Why?
|
Pilot Projects | 2 | 2021 | 8733 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 305 | 0.030 |
Why?
|
Glioblastoma | 1 | 2011 | 3459 | 0.030 |
Why?
|
Benzylamines | 1 | 2017 | 251 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2022 | 14652 | 0.030 |
Why?
|
Heterocyclic Compounds | 1 | 2017 | 245 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 2013 | 4274 | 0.030 |
Why?
|
Thalidomide | 3 | 2006 | 886 | 0.030 |
Why?
|
Pelvis | 1 | 2020 | 738 | 0.030 |
Why?
|
Tumor Escape | 1 | 2019 | 371 | 0.030 |
Why?
|
Vascular Diseases | 1 | 2004 | 1159 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1624 | 0.030 |
Why?
|
Autopsy | 1 | 2019 | 1011 | 0.030 |
Why?
|
Propensity Score | 1 | 2023 | 1968 | 0.030 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2014 | 5753 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 786 | 0.030 |
Why?
|
Ubiquitin-Activating Enzymes | 1 | 2015 | 84 | 0.030 |
Why?
|
Treatment Refusal | 1 | 2018 | 433 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 1002 | 0.030 |
Why?
|
Up-Regulation | 2 | 2017 | 4137 | 0.030 |
Why?
|
Pelvic Bones | 1 | 2017 | 274 | 0.030 |
Why?
|
Spiral Cone-Beam Computed Tomography | 1 | 2015 | 32 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2008 | 8041 | 0.030 |
Why?
|
Carboplatin | 2 | 2011 | 789 | 0.030 |
Why?
|
Stomach Diseases | 1 | 2015 | 134 | 0.030 |
Why?
|
Collagen | 1 | 2002 | 2618 | 0.030 |
Why?
|
Receptors, CXCR | 1 | 2014 | 52 | 0.030 |
Why?
|
Nitric Oxide | 1 | 2003 | 2143 | 0.030 |
Why?
|
Adolescent | 5 | 2014 | 88835 | 0.030 |
Why?
|
Incidence | 3 | 2021 | 21480 | 0.030 |
Why?
|
Hepatectomy | 1 | 2017 | 589 | 0.030 |
Why?
|
Polyps | 1 | 2015 | 200 | 0.030 |
Why?
|
Karnofsky Performance Status | 1 | 2013 | 163 | 0.030 |
Why?
|
Antigen-Presenting Cells | 1 | 2017 | 962 | 0.030 |
Why?
|
Glycosaminoglycans | 1 | 2016 | 606 | 0.030 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2009 | 614 | 0.030 |
Why?
|
Doxorubicin | 3 | 2006 | 2230 | 0.030 |
Why?
|
Adenomatous Polyposis Coli Protein | 1 | 2014 | 182 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2021 | 3160 | 0.030 |
Why?
|
Hyaluronic Acid | 1 | 2016 | 484 | 0.030 |
Why?
|
DNA Methylation | 1 | 2007 | 4424 | 0.030 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 268 | 0.030 |
Why?
|
Risk | 1 | 2004 | 9591 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1587 | 0.020 |
Why?
|
Threonine | 1 | 2013 | 272 | 0.020 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1365 | 0.020 |
Why?
|
RNA | 1 | 2022 | 2717 | 0.020 |
Why?
|
Cell Proliferation | 2 | 2018 | 10429 | 0.020 |
Why?
|
Palliative Care | 2 | 2005 | 3645 | 0.020 |
Why?
|
Liver Function Tests | 1 | 2013 | 525 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2016 | 1886 | 0.020 |
Why?
|
Laparoscopy | 1 | 2003 | 2039 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2018 | 1737 | 0.020 |
Why?
|
Inpatients | 1 | 2023 | 2564 | 0.020 |
Why?
|
Colon | 1 | 2019 | 1795 | 0.020 |
Why?
|
Genes, ras | 1 | 2014 | 658 | 0.020 |
Why?
|
Mice, Nude | 1 | 2018 | 3618 | 0.020 |
Why?
|
Age of Onset | 1 | 2018 | 3344 | 0.020 |
Why?
|
Cadherins | 1 | 2016 | 900 | 0.020 |
Why?
|
Genes, erbB-2 | 1 | 2011 | 160 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12056 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2024 | 3615 | 0.020 |
Why?
|
Medical Oncology | 1 | 2022 | 2339 | 0.020 |
Why?
|
Methionine | 1 | 2013 | 569 | 0.020 |
Why?
|
Drug Costs | 1 | 2018 | 1193 | 0.020 |
Why?
|
Dendritic Cells | 1 | 2021 | 2747 | 0.020 |
Why?
|
Herpesvirus 4, Human | 1 | 2016 | 1078 | 0.020 |
Why?
|
Weather | 1 | 2011 | 234 | 0.020 |
Why?
|
Gastrointestinal Hemorrhage | 2 | 2010 | 1127 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2002 | 5125 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2024 | 3529 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2017 | 6113 | 0.020 |
Why?
|
Brain Ischemia | 1 | 2003 | 3000 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3050 | 0.020 |
Why?
|
Survival | 1 | 2010 | 160 | 0.020 |
Why?
|
Interleukin-6 | 2 | 2009 | 3222 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 4562 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2017 | 1944 | 0.020 |
Why?
|
Kenya | 1 | 2011 | 758 | 0.020 |
Why?
|
Extracellular Matrix | 1 | 2016 | 1727 | 0.020 |
Why?
|
Oncogene Protein v-akt | 1 | 2008 | 130 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2006 | 10383 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2018 | 2589 | 0.020 |
Why?
|
Hospitalization | 2 | 2023 | 10808 | 0.020 |
Why?
|
Cause of Death | 1 | 2019 | 3708 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2017 | 3421 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2016 | 11022 | 0.020 |
Why?
|
Australia | 1 | 2011 | 1258 | 0.020 |
Why?
|
Drug Industry | 1 | 2014 | 791 | 0.020 |
Why?
|
Vitamin B Complex | 1 | 2010 | 299 | 0.020 |
Why?
|
Vision Disorders | 1 | 2014 | 1087 | 0.020 |
Why?
|
Cell Cycle Proteins | 2 | 2010 | 3430 | 0.020 |
Why?
|
Vitamin B 12 | 1 | 2010 | 532 | 0.020 |
Why?
|
Bone Marrow | 1 | 2017 | 2921 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2017 | 14448 | 0.020 |
Why?
|
Genetic Testing | 1 | 2019 | 3595 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2009 | 1701 | 0.020 |
Why?
|
Demography | 1 | 2011 | 1641 | 0.020 |
Why?
|
Cell Count | 1 | 2010 | 1823 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7232 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 1731 | 0.020 |
Why?
|
Chronic Disease | 1 | 2021 | 9347 | 0.020 |
Why?
|
Carcinoma, Islet Cell | 1 | 2006 | 21 | 0.020 |
Why?
|
Heterozygote | 1 | 2013 | 2794 | 0.020 |
Why?
|
Upper Gastrointestinal Tract | 1 | 2006 | 46 | 0.020 |
Why?
|
Patient Selection | 2 | 2011 | 4255 | 0.020 |
Why?
|
Nanoparticles | 1 | 2017 | 1964 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2018 | 5526 | 0.020 |
Why?
|
Epirubicin | 1 | 2005 | 82 | 0.020 |
Why?
|
Ifosfamide | 1 | 2006 | 233 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4405 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 1 | 2010 | 1066 | 0.020 |
Why?
|
Serine Endopeptidases | 1 | 2010 | 1024 | 0.020 |
Why?
|
alpha-Fetoproteins | 1 | 2006 | 226 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2014 | 4860 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 3596 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2018 | 3111 | 0.010 |
Why?
|
Clinical Laboratory Techniques | 1 | 2010 | 747 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5370 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 314 | 0.010 |
Why?
|
Ultrasonography | 2 | 2011 | 5993 | 0.010 |
Why?
|
Streptozocin | 1 | 2004 | 189 | 0.010 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 372 | 0.010 |
Why?
|
Hemoglobins | 1 | 2010 | 1530 | 0.010 |
Why?
|
Abdominal Pain | 1 | 2011 | 1069 | 0.010 |
Why?
|
Qualitative Research | 1 | 2015 | 3139 | 0.010 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2018 | 4642 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15398 | 0.010 |
Why?
|
Hydroxyindoleacetic Acid | 1 | 2004 | 94 | 0.010 |
Why?
|
Intraoperative Period | 1 | 2005 | 508 | 0.010 |
Why?
|
Academic Medical Centers | 1 | 2014 | 2780 | 0.010 |
Why?
|
Life Tables | 1 | 2004 | 363 | 0.010 |
Why?
|
Terminally Ill | 1 | 2005 | 241 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14751 | 0.010 |
Why?
|
Vaccines, Conjugate | 1 | 2005 | 334 | 0.010 |
Why?
|
Mice, Congenic | 1 | 2003 | 98 | 0.010 |
Why?
|
Diarrhea | 1 | 2010 | 1316 | 0.010 |
Why?
|
Risk Assessment | 3 | 2011 | 24282 | 0.010 |
Why?
|
Folic Acid | 1 | 2010 | 1338 | 0.010 |
Why?
|
Octreotide | 1 | 2004 | 157 | 0.010 |
Why?
|
Laser-Doppler Flowmetry | 1 | 2003 | 236 | 0.010 |
Why?
|
Nitric Oxide Synthase Type I | 1 | 2003 | 171 | 0.010 |
Why?
|
Leukocytes | 1 | 2010 | 2027 | 0.010 |
Why?
|
Dexamethasone | 1 | 2010 | 1963 | 0.010 |
Why?
|
Endostatins | 1 | 2002 | 167 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2013 | 4772 | 0.010 |
Why?
|
Drugs, Investigational | 1 | 2004 | 211 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2019 | 4873 | 0.010 |
Why?
|
Crosses, Genetic | 1 | 2003 | 752 | 0.010 |
Why?
|
Topotecan | 1 | 2002 | 130 | 0.010 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2002 | 108 | 0.010 |
Why?
|
Nitric Oxide Synthase Type II | 1 | 2003 | 512 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4034 | 0.010 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2005 | 679 | 0.010 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2002 | 122 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9338 | 0.010 |
Why?
|
RNA, Messenger | 2 | 2009 | 12768 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2009 | 3797 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6069 | 0.010 |
Why?
|
Colectomy | 1 | 2006 | 697 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 2003 | 1377 | 0.010 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2002 | 594 | 0.010 |
Why?
|
Drug Approval | 1 | 2007 | 818 | 0.010 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2006 | 1314 | 0.010 |
Why?
|
Endothelial Growth Factors | 1 | 2002 | 680 | 0.010 |
Why?
|
Drug Combinations | 1 | 2006 | 2077 | 0.010 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2003 | 707 | 0.010 |
Why?
|
Blood Platelets | 1 | 2010 | 2464 | 0.010 |
Why?
|
Pharmacogenetics | 1 | 2004 | 682 | 0.010 |
Why?
|
Genomics | 1 | 2015 | 5929 | 0.010 |
Why?
|
Lymphokines | 1 | 2002 | 911 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2006 | 3750 | 0.010 |
Why?
|
Microcirculation | 1 | 2004 | 1280 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2002 | 745 | 0.010 |
Why?
|
Colonic Polyps | 1 | 2004 | 556 | 0.010 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2008 | 2878 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 13039 | 0.010 |
Why?
|
Risk Factors | 2 | 2020 | 74840 | 0.010 |
Why?
|
Recurrence | 1 | 2011 | 8501 | 0.010 |
Why?
|
United States Food and Drug Administration | 1 | 2007 | 1672 | 0.010 |
Why?
|
Pneumonectomy | 1 | 2006 | 1128 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2005 | 1857 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 2010 | 3401 | 0.010 |
Why?
|
Sex Factors | 1 | 2012 | 10603 | 0.010 |
Why?
|
Parietal Lobe | 1 | 2003 | 858 | 0.010 |
Why?
|
Europe | 1 | 2004 | 3423 | 0.010 |
Why?
|
DNA Primers | 1 | 2002 | 2825 | 0.010 |
Why?
|
Safety | 1 | 2002 | 1157 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2014 | 7851 | 0.010 |
Why?
|
Signal Transduction | 2 | 2011 | 23601 | 0.010 |
Why?
|
Corpus Striatum | 1 | 2003 | 1218 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2005 | 2453 | 0.010 |
Why?
|
Creatinine | 1 | 2002 | 1915 | 0.010 |
Why?
|
Pregnancy | 1 | 2018 | 30260 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2006 | 2844 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2009 | 3584 | 0.010 |
Why?
|
Stem Cells | 1 | 2009 | 3540 | 0.010 |
Why?
|
United States | 3 | 2011 | 72903 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2011 | 12976 | 0.010 |
Why?
|
Cytokines | 1 | 2010 | 7421 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2005 | 2796 | 0.010 |
Why?
|
Base Sequence | 1 | 2005 | 12403 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2002 | 2002 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 18071 | 0.010 |
Why?
|
Adenoma | 1 | 2004 | 2152 | 0.010 |
Why?
|
Polymorphism, Genetic | 1 | 2004 | 4247 | 0.010 |
Why?
|
Motor Activity | 1 | 2003 | 2704 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 2003 | 2674 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2002 | 6493 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2004 | 3454 | 0.010 |
Why?
|
Research Design | 1 | 2003 | 6209 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2003 | 20124 | 0.000 |
Why?
|
DNA-Binding Proteins | 1 | 2002 | 9601 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2003 | 18293 | 0.000 |
Why?
|
Child | 1 | 2011 | 80564 | 0.000 |
Why?
|